

Supplemental File 2: Schedule of Events Table:

Study Period	Week #	Participant/ study team interaction
Pre-Intervention Period	-4	Clinic visit – education, baseline physical and neurological review and urine test for THC for those only who have not been on cannabinoids for at least last 60 days.
Baseline analysis	-4 to 0	Participant parent/legal guardian completion of seizure diary; 24 hour ambulatory EEG, psychologist will arrange for parent/caregiver to complete a Vineland assessment
Intervention period	0	Clinic visit – education, weight, physical and neurological review; baseline bloodwork; collection of baseline seizure diary; education regarding dosing of study product; parent to complete baseline QOLCE
	1	Telephone and/ or email contact by study team to determine dosing and tolerability
	2	Clinic visit – tolerance review, adverse events,; physical and neurological exam; parent/legal guardian to complete PESQ; seizure diary review
	3	Telephone and/ or email contact by study team to determine dosing and tolerability
	4	Clinic visit – tolerance review, adverse events; physical and neurological exam; parent/legal guardian to complete PESQ; seizure diary review; bloodwork
	5	Telephone and/ or email contact by study team to determine dosing and tolerability
	6	Telephone and/ or email contact by study team to determine dosing and tolerability
	7	Telephone and/ or email contact by study team to determine dosing and tolerability
	8	Clinic visit – tolerance review, adverse events; physical and neurological exam; parent/legal guardian to complete PESQ and QOLCE; seizure diary review; bloodwork performed once child is at target / maximal tolerated dose (any stage from week 8-16)
	10	Telephone and/ or email contact by study team to determine dosing and tolerability
12	Clinic visit – tolerance review, adverse events; physical and neurological exam; parent/legal guardian to complete PESQ; seizure diary review; bloodwork performed once at target / maximal tolerated dose (if not done previously)	

	14	Telephone and/ or email contact by study team to determine dosing and tolerability
	16	Clinic visit – tolerance review, adverse events; physical and neurological exam; parent/legal guardian to complete PESQ and QOLCE; seizure diary review; bloodwork performed once at target / maximal tolerated dose(if not done previously)
Primary Analysis	16-20	Telephone and/ or email contact by study team at 18 weeks to determine dosing and tolerability Psychologist will arrange for parent/legal guardian to complete a Vineland assessment Participant parent/legal guardian completion of seizure diary during this 4 weeks; 24 hour ambulatory EEG. Collection of seizure diary reported seizure frequency.
Longitudinal follow-up period (if participant chooses to continue)	28	<i>Clinic visit – tolerance review; physical and neurological exam; parent/legal guardian to complete PESQ and QOLCE; seizure diary review;</i>
	40	<i>Clinic visit – tolerance review; physical and neurological exam; parent/legal guardian to complete PESQ; seizure diary review;</i> <i>Follow up bloodwork performed once (any stage from week 40-64)</i>
	52	<i>Clinic visit – tolerance review; physical and neurological exam; parent/legal guardian to complete PESQ and QOLCE; seizure diary review;</i> <i>Follow up blood work performed once (if not done previously)</i> <i>During 52-64 weeks psychologist will arrange for parent/caregiver to complete a Vineland assessment</i>
	64	<i>Clinic visit – tolerance review; physical and neurological exam; parent/legal guardian to complete PESQ; seizure diary review</i> <i>Follow up blood work performed once (if not done previously)</i>